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Excessive daytime sleepiness (EDS) is a ubiquitous problem that affects public health and safety. A test that can reliably identify
individuals that suffer from EDS is needed. In contrast to other methods, salivary biomarkers are an objective, inexpensive, and
noninvasive method to identify individuals with inadequate sleep. Although we have previously shown that inflammatory genes
are elevated in saliva samples taken from sleep deprived individuals, it is unclear if inflammatory genes will be elevated in clinical
populations with EDS. In this study, salivary samples from individuals with sleep apnea were evaluated using the Taqman low
density inflammation array. Transcript levels for 3 genes, including prostaglandin-endoperoxide synthase 2 (PTGS2), were elevated
in patients with sleep apnea. Interestingly, PTGS2 was also elevated in patients with EDS but who did not have sleep apnea. These
data demonstrate the feasibility of using salivary transcript levels to identify individuals that self-report excessive daytime sleepiness.
1. Introduction
Inadequate sleep is a pervasive problem in today’s society.
Insufficient sleep leads to decreased cognitive performance
[1], increased sleepiness [2–4], reduced productivity [5], and
increased traffic accidents [6]. Moreover, inadequate sleep
increases the susceptibility of individuals to adverse health
outcomes, including cardiovascular deficits [7], increased
immune challenges [8, 9], longer recovery times after injury
[10], increases in sympathetic tone [11, 12], and reduced
lifespan [7]. Given the number and severity of consequences
that accompany inadequate sleep, it would be helpful to have
a simple and reliable test to identify vulnerable individuals
before they experience adverse consequences.
One approach to accomplish this objective has been to
test candidate biomarkers to determine whether they are
consistently altered in subjects with inadequate or insufficient
sleep. Biomarkers are objective, often endogenous factors that
report changes in body chemistry and correlate with either
disease state or the severity of the disease. Several biomarkers,
including eyelid closures [13] and balance [14], as well as
biochemical markers from blood [15, 16], cerebral spinal
fluid [17–19], and breath analytes [20] have been evaluated
as candidate biomarkers of disrupted sleep. Although each
of these approaches has had limited success, assessment
tools that can be used in real-world settings are not yet
widely available. With that in mind, we have hypothesized
that saliva, as a rich source of analytes, can be mined
to identify biomarkers of sleepiness or inadequate sleep.
Saliva is particularly well suited for monitoring sleepiness
since it is a readily accessible biological fluid that can be
easily collected using noninvasive procedures. Indeed, we
have shown that transcripts for 𝛼-amylase, Filamin-A,maleic
enzyme, integrin, 𝛼M, and integrin, 𝛼5, are all elevated in
saliva samples following sleep deprivation [21–24]. Increased
levels of salivary 𝛼-amylase activity have also been shown to
correlate with increased sleepiness and decreased cognitive
performance in an independent study [25]. However, since
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endogenous factors are frequently modulated by a variety of
physiological conditions (stress, circadian time, etc.), test of
sleepiness should be comprised of a panel of independent
analytes. Several studies have found that serum markers of
inflammation are elevated in populations of individuals with
sleep disorders [9]. For example, serum levels of interleukin
6 (IL-6) [26], interleukin 8 (IL-8) [27, 28], tumor necrosis
factor-𝛼 (TNF-𝛼) [29], C-reactive protein (CRP) [30], intra-
cellular adhesion molecule (ICAM) [31], selectins [32], and
vascular cell adhesion molecule (VCAM) [31] have all been
shown to increase in multiple populations of patients with
sleep apnea. Therefore, we wanted to determine if levels of
salivary inflammation transcripts could be used to identify
sleepiness in a clinical population, individuals diagnosedwith
sleep apnea.
2. Materials and Methods
2.1. Subjects and Samples. 8 controls, 14 patients confirmed
to have sleep apnea, and 18 patients that were suspected
to have sleep apnea during their initial screen but did
not exhibit sleep apnea during their overnight assessment
(sleepy) were evaluated for salivary transcript levels. Both the
sleep apnea group and the “sleepy” group were referred to
theWashington University Sleep Laboratory due to excessive
sleepiness. Samples were taken from patients at ∼9 pm after
they had arrived at the sleep lab and prior to beginning
polysomnography. The apnea/hypopnea index (AHI) was
determined using polysomnography (PSG) as previously
described [33]. Subjects were free from psychiatric disorders
and prescription medicines [24]. Each subject was admin-
istered the Epworth Sleepiness Scale (ESS) and their body
mass index (BMI) was calculated. BMI was unavailable for
one subject in the “sleepy” group. Consent was received
from all participants and all protocols were approved by
the Washington University School of Medicine Institutional
Review Board.
2.2. Low Density Arrays. Saliva was taken and cDNA was
generated according to the protocol previously described
[24]. Briefly, saliva was obtained when subjects chewed on a
salivette (Sarstedt, Newton, NC). OnemL of RNAlater (Life
Technologies, Grand Island, NY) was added to the salivette
and immediately frozen on dry ice and stored at −80∘C. At
the time of transcript analysis, salivettes were thawed and
the saliva-RNAlater extracts were extracted by centrifuga-
tion. RNA was purified from cell-free lysates and reverse-
transcribed using Superscript III (Life Technologies, Grand
Island, NY) according to the manufacturer’s instructions.
Equal amounts of cDNA were loaded into an inflammation
Taqman low density array (LDA) (Life Technologies, Grand
Island, NY) and Taqman based qPCR was carried out using
the 7600 real-time PCR system (Applied Biosystems, Foster
City, CA). The LDAs were normalized to 18S RNA. Fold
changeswere determined using themethod described in [34],
known as the comparative C
𝑇
method. Transcript levels for
the gene of interest were first normalized within subject to
18S RNA.
Table 1: Demographics for controls and sleep apnea.
Controls (𝑛 = 8) OSA (𝑛 = 14)
Gender 5M, 3F 11M, 3F
Age 40.8 ± 8.9 49.0 ± 12.2
AHI — 48.5 ± 23.6
BMI∗ 25.7 ± 4.4 34.6 ± 7.1
ESS∗ 3.9 ± 2.7 10.8 ± 4.3
Ave. ± Std. Dev.; ∗𝑃 < 0.05.
2.3. Statistics. All demographic data is presented as average ±
standard deviation. For transcript analysis, if a transcript was
not detected in more than 77% of the group, the transcript
was deemed undetectable and not analyzed. For all detectable
genes, transcript levels for each subject were determined as
a fold change from the average levels of the control group.
Fold changes were converted to a log
2
scale. From the log
data, average and standard error were calculated. Groups of
interest were compared to control levels using a two-tailed,
unpaired Student’s t-test and the significance level was set
at 0.05. 𝑃 values were corrected for multiple comparisons
using the false discovery method (FDR) with a FDR level
of 5% [35]. Transcript levels are presented as a geometric
mean and standard error [36]. For ease of presentation, group
data, including average, upper, and lower bounds, were then
converted back to standard units by raising 2 to the power of
the calculated value to obtain fold change values.
3. Results
3.1. Demographic Data for Patients with Sleep Apnea. We
evaluated 14 patients with sleep apnea (11 male and 3 female)
and 8 control subjects (5 male and 3 female) for salivary
transcriptional changes associated with sleep apnea. Control
subjects did not have any prior existing sleep or mental
disorders, were not on prescriptionmedications, had not con-
sumed caffeine, and had not eaten 1 hour prior to providing
a saliva sample. Subject age was not different between the
two groups (Table 1). The subjects with sleep apnea had an
average AHI of 48.5 ± 23.6 (mean ± S.D.). The subjects with
sleep apnea had a significantly higher bodymass index (BMI)
than the controls. Consistent with previous results, subjects
with sleep apnea also reported a higher score on the Epworth
Sleepiness Scale.
3.2. Evaluation of Salivary Biomarkers Associated with Inflam-
mation in Patients with Sleep Apnea. We evaluated salivary
transcript levels from subjects with sleep apnea and control
subjects using low density arrays. The LDA platform simul-
taneously evaluates the levels of 96 RNA species. Of the 96
genes tested, 21 transcripts were detected in 11 or more sleep
apnea patients. Fold changes from control and 𝑃 value for
each gene are presented in Table 2. The 𝑃 value listed was
determined using a two-tailed Student’s t-test comparing the
controls to sleep apnea for all analyzed genes present in saliva.
We performed a correction for multiple comparisons using
a FDR set at 5%, which yielded a new 𝑃 value equivalent to
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Table 2: Salivary transcript levels in patients with sleep apnea compared to controls.
Gene Abbreviation Sleep apnea fold Δ fromcontrola 𝑃 value
𝛽-actin ACTB 1.43 ± 0.38 0.191
Arachidonate 5-lipoxygenase ALOX5 1.39 ± 0.36 0.238
Arachidonate 12-lipoxygenase ALOX12 1.56 ± 0.69 0.404
Annexin A1 ANXA1 4.62 ± 1.15 0.003b
Annexin A3 ANXA3 1.26 ± 0.38 0.444
Annexin A5 ANXA5 2.05 ± 0.92 0.168
𝛽-2-microglobulin B2M 2.65 ± 0.70 0.007b
Caspase 1, apoptosis-related cysteine peptidase CASP1 2.57 ± 0.81 0.025
Glyceraldehyde-3-phosphate dehydrogenase GAPDH 2.66 ± 0.81 0.019
Intercellular adhesion molecule 1 ICAM1 0.44 ± 0.13 0.123
Interleukin 1 receptor, type II IL1R2 1.62 ± 0.41 0.143
Interleukin 2 receptor, gamma IL2RG 2.36 ± 0.72 0.054
Integrin, alpha M ITGAM 1.50 ± 0.61 0.376
Integrin, beta 2 ITGB2 1.47 ± 0.31 0.167
Mitogen-activated protein kinase 1 MAPK1 1.72 ± 0.66 0.401
Mitogen-activated protein kinase 3 MAPK3 1.30 ± 0.41 0.585
Mitogen-activated protein kinase 14 MAPK14 1.85 ± 0.53 0.089
Phosphodiesterase 4B, cAMP-specific PDE4B 1.49 ± 0.21 0.168
Prostaglandin-endoperoxide synthase 2 (prostaglandin
G/H synthase and cyclooxygenase) PTGS2 3.73 ± 0.98 0.002
b
Tumor necrosis factor receptor superfamily, member 1A TNFRSF1A 1.32 ± 0.20 0.206
Tumor necrosis factor receptor superfamily, member 1B TNFRSF1B 1.07 ± 0.44 0.900
aMean ± SEM.
bSignificant difference using 5% FDR post hoc test.
𝛼 = 0.0071 [35]. Compared to controls, 3 transcripts exhibited
significant changes in patients with sleep apnea (Table 2),
ANXA1, 𝛽2M, and PTGS2 (see Table 2 for abbreviations).
These results indicate that several inflammatory transcripts
are increased in patients with sleep apnea.
3.3. Demographic Data for Patients with an Elevated ESS
but without Sleep Apnea. To assess whether the increased
inflammatory markers were due primarily to hypoxia or
whether theymight bemore closely associatedwith increased
sleepiness, we evaluated transcriptional changes in an inde-
pendent group of people that entered the sleep lab suspected
of having sleep apnea due to initial screening but ultimately
had a normal AHI as determined by PSG (sleepy). The
“sleepy” group was composed of 6 males and 12 females. By
definition, all individuals in this grouphad anAHI less than 5.
However, all subjects reported ESS scores significantly higher
than controls and similar to the subjects with sleep apnea
(Tables 1 and 3). “Sleepy” subjects had a similar age to controls
but an increased BMI.
3.4. Salivary Transcript Levels in “Sleepy” People. Twenty-
one transcripts were detected in the saliva of 14 or more
“sleepy” patients. As above, to facilitate comparisons with
the apnea patients reported in Table 2, Table 4 includes
Table 3: Demographics for “sleepy” subjects and controls.
Controls (𝑛 = 8) Sleepy (𝑛 = 18)
Gender 5M, 3F 6M, 12F
Age 40.8 ± 8.9 44.1 ± 14.4
AHI — 4.7 ± 5.2
BMI∗ 25.7 ± 4.4 34.2 ± 10.8
ESS∗ 3.9 ± 2.7 11.0 ± 5.0
Ave ± Std. Dev.; ∗𝑃 < 0.05.
transcripts for fold changes for each of the 21 transcripts.
After and FDR correction for multiple comparisons (𝛼 =
0.005), 2 transcripts were significantly changed in the “sleepy”
population, CASP1 and PTGS2. PTGS2 can be considered an
independent replicate of the apnea results and may deserve
further consideration. Thus, inflammatory transcripts are
elevated under conditions of EDS.
3.5. Transcriptional Changes Are Not due to Elevated BMI.
One possible explanation for elevated inflammatory tran-
scripts is that both the sleep apnea and “sleepy” patients
have a significantly higher BMI compared to controls. If the
observed relationship is due solely to BMI, then patients with
high BMI should have increased levels of inflammatory tran-
scripts compared to patients with lower BMI. Similarly, we
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Table 4: Salivary transcript levels in “sleepy” patients compared to controls.
Gene Abbreviation Sleepy people fold Δfrom controla 𝑃 value
𝛽-actin ACTB 1.86 ± 0.47 0.033
Arachidonate 5-lipoxygenase ALOX5 1.30 ± 0.46 0.472
Arachidonate 12-lipoxygenase ALOX12 0.53 ± 0.33 0.408
Annexin A1 ANXA1 2.86 ± 1.37 0.099
Annexin A3 ANXA3 2.64 ± 0.85 0.010
Annexin A5 ANXA5 2.29 ± 0.76 0.054
𝛽-2-microglobulin B2M 3.33 ± 1.34 0.013
Caspase 1, apoptosis-related cysteine peptidase CASP1 5.36 ± 2.07 0.001b
Glyceraldehyde-3-phosphate dehydrogenase GAPDH 2.35 ± 0.88 0.068
Intercellular adhesion molecule 1 ICAM1 0.61 ± 0.33 0.441
Interleukin 1 receptor, type II IL1R2 2.04 ± 0.75 0.092
Interleukin 2 receptor, gamma IL2RG 3.53 ± 2.25 0.118
Integrin, alpha M ITGAM 1.64 ± 0.65 0.292
Integrin, beta 2 ITGB2 1.84 ± 0.52 0.102
Mitogen-activated protein kinase 1 MAPK1 1.55 ± 0.65 0.510
Mitogen-activated protein kinase 3 MAPK3 1.06 ± 0.42 0.921
Mitogen-activated protein kinase 14 MAPK14 2.33 ± 0.77 0.057
Phosphodiesterase 4B, cAMP-specific PDE4B 1.69 ± 0.69 0.259
Prostaglandin-endoperoxide synthase 2 (prostaglandin
G/H synthase and cyclooxygenase) PTGS2 3.80 ± 1.34 0.005
b
Tumor necrosis factor receptor superfamily, member 1A TNFRSF1A 1.87 ± 0.62 0.096
Tumor necrosis factor receptor superfamily, member 1B TNFRSF1B 1.80 ± 0.88 0.322
aMean ± SEM.
bSignificant difference using 5% FDR post hoc test.
should detect a significant positive correlation between BMI
and the level of salivary transcripts. To test this hypothesis
we discretized the data by placing the subjects with a low
BMI (≤30; 𝑛 = 24) into a single group and comparing
them to subjects with a high BMI (>38; 𝑛 = 16). As
seen in Table 5, transcripts were not significantly different
between subjects in the lower BMI group compared to their
counterparts with a higher BMI. In addition, we evaluated
the relationship between BMI and transcript levels using a
Pearson correlation and found no significant correlations.
Examples of transcript expression levels for the geneswith the
lowest 𝑃 values are plotted in Figure 1 as a function of BMI.
These data indicate that, in this dataset, BMI does not account
for increases in transcript levels in these patients.
4. Discussion
In this paper, we report that salivary transcript levels of
inflammatory genes are increased both in patients with
sleep apnea and in an independent cohort of patients who
self-identified as sleepy and were referred to the sleep lab
suspected of having sleep apnea. We have previously used
these same human low density arrays as a discovery tool
to identify genes that are modified following acute sleep
deprivation in healthy adults [24]. In that study, we reported
that integrin, 𝛼M (ITGAM), and annexin A3 (ANXA3) were
significantly increased following 24 h and 30 h of waking.
Interestingly, neither ITGAM nor ANXA3 were altered in
either sleep apnea or “sleepy” subjects suggesting that they
may be better suited for detecting acute sleep loss than
for identifying patients with chronic sleep disruption. In
contrast, salivary PTGS2 was significantly increased in both
sleep apnea patients and in the “sleepy” cohort but was not
affected by acute sleep deprivation [24]. Thus, these data
support our previous proposal that a panel of biomarkers will
be required to accurately identify sleep deprived individuals
and further suggest that different sets of biomarkers may
be required to distinguish between acute and chronic sleep
disruptions.
Sleep apnea has been particularly difficult to diagnose and
treat and the incidence of sleep apnea has been difficult to
determine. Estimates of sleep apnea have ranged from as low
as 2–4% to as high as 24% of middle aged men [37], although
other studies have estimated the likelihood of sleep apnea to
be much higher still [38, 39]. Moreover, it has been suggested
that sleep apnea is likely to be substantially underdiagnosed
[38, 39]. Indeed, years may transpire between the onset of
sleep apnea and the eventual diagnosis [40]. As the popula-
tion ages and becomes more obese, the prevalence of sleep
apnea is expected to increase even further [7, 41, 42]. During
these intervening years, the severity and consequences of
the sleep apnea may also increase [41, 42]. The associated
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Table 5: Comparison of transcriptional changes in high and low BMI subjects.
Gene Abbreviation BMI < 30 BMI > 30 𝑡-test
fold Δa,b fold Δa,c
𝛽-actin ACTB 1.39 ± 0.29 1.65 ± 0.40 0.438
Arachidonate 5-lipoxygenase ALOX5 1.46 ± 0.33 0.97 ± 0.28 0.117
Arachidonate 12-lipoxygenase ALOX12 1.25 ± 0.47 0.48 ± 0.32 0.058
Annexin A1 ANXA1 3.06 ± 1.25 2.33 ± 1.03 0.529
Annexin A3 ANXA3 1.68 ± 0.40 1.63 ± 0.61 0.913
Annexin A5 ANXA5 1.74 ± 0.58 2.17 ± 0.75 0.519
𝛽-2-microglobulin B2M 1.95 ± 0.66 3.12 ± 0.91 0.156
Caspase 1, apoptosis-related cysteine peptidase CASP1 2.68 ± 0.90 3.05 ± 1.42 0.741
Glyceraldehyde-3-phosphate dehydrogenase GAPDH 2.14 ± 0.72 1.94 ± 0.57 0.771
Intercellular adhesion molecule 1 ICAM1 0.61 ± 0.22 0.62 ± 0.36 0.982
Interleukin 1 receptor, type II IL1R2 1.88 ± 0.53 1.24 ± 0.34 0.153
Interleukin 2 receptor, gamma IL2RG 2.65 ± 1.37 2.20 ± 0.93 0.713
Integrin, alpha M ITGAM 1.56 ± 0.48 1.25 ± 0.51 0.537
Integrin, beta 2 ITGB2 1.52 ± 0.35 1.54 ± 0.38 0.949
Mitogen-activated protein kinase 1 MAPK1 1.77 ± 0.83 1.20 ± 0.37 0.355
Mitogen-activated protein kinase 3 MAPK3 1.41 ± 0.36 0.90 ± 0.34 0.156
Mitogen-activated protein kinase 14 MAPK14 2.18 ± 0.60 1.51 ± 0.45 0.211
Phosphodiesterase 4B, cAMP-specific PDE4B 1.44 ± 0.36 1.44 ± 0.55 0.999
Prostaglandin-endoperoxide synthase 2 (prostaglandin
G/H synthase and cyclooxygenase) PTGS2 2.43 ± 0.84 3.42 ± 1.13 0.338
Tumor necrosis factor receptor superfamily, member 1A TNFRSF1A 1.47 ± 0.36 1.40 ± 0.33 0.841






consequences of sleep apnea include increased daytime
sleepiness [3] and an increased likelihood of automobile
accidents [6]. Moreover, sleep apnea has been associated with
a host of cardiovascular complications [43, 44] and increased
rates of all-cause mortality [7]. Sleep apnea has also been
associated with learning impairments [45]. The current gold
standard of treatment, continuous positive airway pressure
(CPAP), may be able to reverse some of the consequences of
sleep apnea, such as sleepiness [2] and restoration of typical
sleep stages [2], and may lower blood pressure [46] but the
literature is less conclusive whether cognitive function is
improved [4, 47].Thus, a clinical goal is to have patients begin
treatment for sleep apnea as soon as possible.
A simple cost-effective biomarker that can be easily used
at the point of care may be a useful tool to convince people to
go to the sleep lab for amore precise diagnosis and treatment.
Since biomarkers are both objective and quantifiable, they
are well suited for persuading an individual that they may
have an underlying affliction that needs greater attention.
In that regard, it is important to note that the well-known
relationship between inflammation and sleep deprivation is
an advantage since many physicians are likely to be familiar
with this relationship and thus more willing to incorporate
such a biomarker into their treatment practices. That is,
numerous inflammatorymarkers, including IL-6 [20, 26, 48],
IL-8 [27, 28, 48], TNF-𝛼 [26], CRP [49, 50], monocyte
chemoattractant protein-1 (MCP-1) [27], ICAM [27, 51],
selectins [51], VCAM [51], nitric oxide [52], and isoprostane
[20], are elevated in body fluids of patients with sleep apnea.
Moreover, proteomics have identified protein biomarkers in
urine [53]. Interestingly, inflammatory markers have also
been associated with sleep deprivation in serum [54, 55] and
saliva in healthy adults [24]. In this study, transcript levels for
PTGS2 were elevated in people with inadequate sleep. Our
results parallel findings in mice in which transcript levels for
PTGS2 are elevated after acute sleep deprivation [56]. PTGS2,
along with PTGS1, is a critical enzyme in prostaglandin
synthesis. Prostaglandins initiate a set of molecular cascades
that result in an inflammatory response. PTGS2 is induced
by several stimuli including proinflammatory signals and
converts arachidonic acid to prostaglandin H2 [57]. Thus,
PTGS2 plays a role in the inflammatory pathway in addition
to being a candidate biomarker for EDS.
It is interesting to note that many studies compare sleep
apnea patients to healthy controls. Although this approach
has been quite successful, our data suggest that other patients
with chronic sleep disruption may also experience some
of the same outcomes as patients with sleep apnea. If this
turns out to be the case, more generally, assessing chronically
sleepy individuals along with patients that have sleep apnea



















































































































Figure 1: Correlation of transcript levels with BMI.The transcript levels were plotted against the log values of the transcript levels for each of
the transcripts that were significant in the sleep apnea or “sleepy” groups. In addition the transcripts with the lowest 𝑃 value were plotted to
determine if there was a significant correlation with increased weight. For each transcript, there was no significant correlation with increased
BMI.
may facilitate the identification of precise deficits that are
due specifically to sleep loss rather than other features of
sleep apnea, such as hypoxia [48]. Nonetheless, our results
emphasize that PTGS2 cannot distinguish between sleepy
patients with and without sleep apnea. While this may
seem disappointing, we believe that any diagnosis of a sleep
disorder should be made by a qualified sleep physician after
fully examining the patient. Indeed, it may not be possible to
identify a biomarker that is specific to a single sleep disorder.
One example of a promising biomarker is cerebrospinal
fluid (CSF) levels of hypocretin-1/orexin (HCRT), which
has emerged from research in the narcolepsy field [18, 58].
CSF levels of hypocretin-1/orexin are lower in narcoleptic
patients. But for patients without cataplexy, decreased CSF
levels of HCRT are not as predictive, even in combination
with the genetic marker DBQ. Moreover, decreases in CSF
levels of HCRT are also associated now, being associated with
other diseases, including dementia with Lewy Body [59] and
Alzheimer’s disease [60] and Kleine-Levin syndrome [58, 61].
This example illustrates the difficulty of a single biomarker
with a given sleep disorder. Nonetheless, a biomarker that can
help primary physicians to identify sleepy individuals may be
extremely useful for ensuring that they get the appropriate
care in a timely manner.
Our protocol has two aspects that may be useful for
the real-world application of biomarkers to identify patients
with sleep disorders. First, acquiring saliva is a noninvasive
procedure and does not, for example, require a private
location for sample collection (e.g., urine) or specialized skills
to acquire samples (e.g., blood). As a consequence, salivary
biomarkers can be readily used both on the roadside and in
a doctor’s office with equal effectiveness. A second advantage
of our protocol is our focus on salivary RNA coupled with
the LDA platform for the rapid detection of 96 transcripts
simultaneously. LDAs may be an effective way to screen
multiple targeted transcripts at once without the burden that
NextGen sequencing frequently demands. One advantage of
using transcript levels as the biomarker is that nucleotide
probes can be generated quickly and are very specific for the
target intended as opposed to having to design an antibody
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against a protein target. Given human variability, the different
roles that genes can play throughout the body (pleiotropy),
and the likelihood that a given analyte will be induced by
a variety of environmental situations, it is likely that no
single biomarker will be ideal for reliable diagnosis of sleep
apnea. Nonetheless, our data suggest that PTGS2 may be
a particularly good candidate for inclusion in a panel of
biomarkers.
There are two potential weaknesses of our study. The
first is the sample size of our groups. Low sample sizes may
identify significant differences within the subgroup that does
not generalize to the rest of the population. In this study, we
have tried to balance the difficulty of completing discovery
experiments with the expense of a human study. Although
our sample size was low for sleep apnea subjects, we were
able to confirm the changes in PTGS2 in a separate cohort
of “sleepy” patients.This confirmation adds to our confidence
thatPTGS2 is a good candidate for followup studies. A second
weakness of this study is that we were not able to control for
the levels of BMI between our control subjects and patients
with sleep apnea or the “sleepy” cohort. To address this issue,
we discretized the subjects into groups with low or high
BMI. Means testing between the two groups indicated the
subjects with low and high BMI were not different from one
another. Moreover, Pearson correlation between BMI and
transcript levels did not reveal any significant associations.
Finally, when examined as a whole, we could find no general
trend of inflammatory genes being elevated in subjects with
higher BMI.Thus, while BMI is a potential confounder, it did
not appear to unduly influence the results of this study.
Biomarkers have the capacity to serve an important need
in maintaining human health. They provide an objective
insight into the goings-on of the body. In particular, there
is a need to identify individuals with sleep problems that
result in EDS. Given the difficulty in identifying individuals,
the consequences of sleep apnea and other sleep disorders,
and the potential that therapy possesses, objective biomarkers
can be a way to convince people to go to the sleep lab
for diagnosis. We have demonstrated the feasibility of using
saliva to identify changes in inflammatory transcripts that
correlate with the presence of EDS. Saliva is an ideal source of
biofluid for a potential source of biomarkers. Obtaining saliva
is a noninvasive and relatively inexpensive process. Further
experiments in larger and independent populations will
determine the precision and validity of these biomarkers, but
these experiments demonstrate that saliva has the potential
to be objective biomarkers to identify subjects with EDS.
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